USA • New York Stock Exchange • NYSE:RDY • US2561352038
The current stock price of RDY is 13.965 USD. In the past month the price increased by 2.12%. In the past year, price increased by 0.58%.
ChartMill assigns a technical rating of 5 / 10 to RDY. When comparing the yearly performance of all stocks, RDY turns out to be only a medium performer in the overall market: it outperformed 49.9% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to RDY. RDY scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.74. The EPS increased by 4.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| Debt/Equity | 0.03 |
45 analysts have analysed RDY and the average price target is 14.92 USD. This implies a price increase of 6.84% is expected in the next year compared to the current price of 13.965.
For the next year, analysts expect an EPS growth of -6.34% and a revenue growth 5.1% for RDY
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.08 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.69 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.57 | 297.222B | ||
| PFE | PFIZER INC | 9.04 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.16 | 121.168B | ||
| ZTS | ZOETIS INC | 18.48 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.62 | 25.456B | ||
| VTRS | VIATRIS INC | 5.7 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.09 | 9.116B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
DR. REDDY'S LABORATORIES-ADR
8-2-337, Road No.3 Banjara Hills
Hyderabad TELANGANA 500-034 IN
CEO: Erez Israeli
Employees: 26944
Phone: 914049002900
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
The current stock price of RDY is 13.965 USD. The price decreased by -0.04% in the last trading session.
DR. REDDY'S LABORATORIES-ADR (RDY) has a dividend yield of 0.66%. The yearly dividend amount is currently 0.09.
RDY has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
The PE ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 18.87. This is based on the reported non-GAAP earnings per share of 0.74 and the current share price of 13.965 USD.
DR. REDDY'S LABORATORIES-ADR (RDY) will report earnings on 2026-05-07, after the market close.
The outstanding short interest for DR. REDDY'S LABORATORIES-ADR (RDY) is 2.15% of its float.